Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - diphenoxylate hydrochloride (unii: w24od7yw48) (diphenoxylate - unii:73312p173g), atropine sulfate (unii: 03j5ze7ka5) (atropine - unii:7c0697dr9i) - diphenoxylate hydrochloride and atropine sulfate tablets are indicated as adjunctive therapy in the management of diarrhea in patients 13 years of age and older. diphenoxylate hydrochloride and atropine sulfate tablets are contraindicated in: - pediatric patients less than 6 years of age due to the risks of respiratory and central nervous system (cns) depression [see warnings ] . - patients with diarrhea associated with pseudomembranous enterocolitis ( clostridium difficile ) or other enterotoxin-producing bacteria due to the risk of gastrointestinal (gi) complications, including sepsis [see warnings ] . - patients with known hypersensitivity to diphenoxylate or atropine. - patients with obstructive jaundice. diphenoxylate hydrochloride and atropine sulfate is classified as a schedule v controlled substance by federal regulation. diphenoxylate hydrochloride is chemically related to the narcotic analgesic meperidine. in doses used for the treatment of diarrhea, whether acute or chronic, dip

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

a-s medication solutions - diphenoxylate hydrochloride (unii: w24od7yw48) (diphenoxylate - unii:73312p173g), atropine sulfate (unii: 03j5ze7ka5) (atropine - unii:7c0697dr9i) - diphenoxylate hydrochloride and atropine sulfate tablets usp are indicated as adjunctive therapy in the management of diarrhea in patients 13 years of age and older. diphenoxylate hydrochloride and atropine sulfate tablets are contraindicated in: diphenoxylate hydrochloride and atropine sulfate tablets are classified as a schedule v controlled substance by federal regulation. diphenoxylate hydrochloride is chemically related to the narcotic analgesic meperidine. in doses used for the treatment of diarrhea, whether acute or chronic, diphenoxylate has not produced addiction. diphenoxylate hydrochloride is devoid of morphine-like subjective effects at therapeutic doses. at high doses it exhibits codeine-like subjective effects. the dose which produces antidiarrheal action is widely separated from the dose which causes central nervous system effects. the insolubility of diphenoxylate hydrochloride in commonly available aqueous media precludes intravenous self-administration. a dose of 100 to 300 mg/day, which is

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

remedyrepack inc. - atropine sulfate (unii: 03j5ze7ka5) (atropine - unii:7c0697dr9i) - atropine sulfate injection, usp, may be given parenterally as a pre-anesthetic medication in surgical patients to reduce salivation and bronchial secretions. it may also be used to suppress vagal activity associated with the use of halogenated hydrocarbons during inhalation anesthesia and reflex excitation arising from mechanical stimulation during surgery. the antispasmodic action of atropine is useful in pylorospasm and other spastic conditions of the gastrointestinal tract. for ureteral and biliary colic, atropine concomitantly with morphine may be indicated. atropine relaxes the upper gi tract and colon during hypotonic radiography. in poisoning by the organic phosphate cholinesterase inhibitors found in certain insecticides and by chemical warfare nerve gases, large doses of atropine relieve the muscarine-like symptoms and some of the central nervous system manifestations. it is also used as an antidote for mushroom poisoning due to muscarine in certain species such as amanita muscaria . atropine sulfate

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

bayshore pharmaceuticals, llc - diphenoxylate hydrochloride (unii: w24od7yw48) (diphenoxylate - unii:73312p173g), atropine sulfate (unii: 03j5ze7ka5) (atropine - unii:7c0697dr9i) - diphenoxylate hydrochloride and atropine sulfate tablets are indicated as adjunctive therapy in the management of diarrhea in patients 13 years of age and older. diphenoxylate hydrochloride and atropine sulfate tablets are contraindicated in: - pediatric patients less than 6 years of age due to the risks of respiratory and central nervous system (cns) depression (see warnings ). - patients with diarrhea associated with pseudomembranous enterocolitis (clostridium difficile ) or other enterotoxin-producing bacteria due to the risk of gastrointestinal (gi) complications, including sepsis (see warnings ). - patients with known hypersensitivity to diphenoxylate or atropine. - patients with obstructive jaundice. diphenoxylate hydrochloride and atropine sulfate tablets are classified as a schedule v controlled substance by federal regulation. diphenoxylate hydrochloride is chemically related to the narcotic analgesic meperidine. in doses used for the treatment of diarrhea, whether acute or chronic, diphenoxylate has not produced addiction. diphenoxylate hydrochloride is devoid of morphine-like subjective effects at therapeutic doses. at high doses it exhibits codeine-like subjective effects. the dose which produces antidiarrheal action is widely separated from the dose which causes central nervous system effects. the insolubility of diphenoxylate hydrochloride in commonly available aqueous media precludes intravenous self-administration. a dose of 100 to 300 mg/day, which is equivalent to 40 to 120 tablets, administered to humans for 40 to 70 days, produced opiate withdrawal symptoms. since addiction to diphenoxylate hydrochloride is possible at high doses, the recommended dosage should not be exceeded.

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

remedyrepack inc. - diphenoxylate hydrochloride (unii: w24od7yw48) (diphenoxylate - unii:73312p173g), atropine sulfate (unii: 03j5ze7ka5) (atropine - unii:7c0697dr9i) - diphenoxylate hydrochloride and atropine sulfate is indicated as adjunctive therapy in the management of diarrhea in patients 13 years of age and older. diphenoxylate hydrochloride and atropine sulfate is contraindicated in: - pediatric patients less than 6 years of age due to the risks of respiratory and central nervous system (cns) depression (see warnings ). - patients with diarrhea associated with pseudomembranous enterocolitis ( clostridium difficile ) or other enterotoxin-producing bacteria due to the risk of gastrointestinal (gi) complications, including sepsis (see warnings ). - patients with known hypersensitivity to diphenoxylate or atropine. - patients with obstructive jaundice. diphenoxylate hydrochloride and atropine sulfate is classified as a schedule v controlled substance by federal regulation. diphenoxylate hydrochloride is chemically related to the narcotic analgesic meperidine. in doses used for the treatment of diarrhea, whether acute or chronic, diphenoxylate has not produced addiction. diphenoxylate hydrochloride is devoid of morphine-like subjective effects at therapeutic doses. at high doses it exhibits codeine-like subjective effects. the dose which produces antidiarrheal action is widely separated from the dose which causes central nervous system effects. the insolubility of diphenoxylate hydrochloride in commonly available aqueous media precludes intravenous self-administration. a dose of 100 to 300 mg/day, which is equivalent to 40 to 120 tablets, administered to humans for 40 to 70 days, produced opiate withdrawal symptoms. since addiction to diphenoxylate hydrochloride is possible at high doses, the recommended dosage should not be exceeded.

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

direct_rx - diphenoxylate hydrochloride (unii: w24od7yw48) (diphenoxylate - unii:73312p173g), atropine sulfate (unii: 03j5ze7ka5) (atropine - unii:7c0697dr9i) - diphenoxylate hydrochloride and atropine sulfate tablets usp are indicated as adjunctive therapy in the management of diarrhea in patients 13 years of age and older. diphenoxylate hydrochloride and atropine sulfate tablets are contraindicated in: • pediatric patients less than 6 years of age due to the risks of respiratory and central nervous system (cns) depression (see warnings). • patients with diarrhea associated with pseudomembranous enterocolitis (clostridium difficile) or other enterotoxin-producing bacteria due to the risk of gastrointestinal (gi) complications, including sepsis (see warnings). • patients with known hypersensitivity to diphenoxylate or atropine. • patients with obstructive jaundice. controlled substance diphenoxylate hydrochloride and atropine sulfate tablets are classified as a schedule v controlled substance by federal regulation. diphenoxylate hydrochloride is chemically related to the narcotic analgesic meperidine. drug abuse and dependence in do

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

hf acquisition co llc, dba healthfirst - atropine sulfate (unii: 03j5ze7ka5) (atropine - unii:7c0697dr9i) - atropine sulfate injection, usp, may be given parenterally as a pre-anesthetic medication in surgical patients to reduce salivation and bronchial secretions. it may also be used to suppress vagal activity associated with the use of halogenated hydrocarbons during inhalation anesthesia and reflex excitation arising from mechanical stimulation during surgery. the antispasmodic action of atropine is useful in pylorospasm and other spastic conditions of the gastrointestinal tract. for ureteral and biliary colic, atropine concomitantly with morphine may be indicated. atropine relaxes the upper gi tract and colon during hypotonic radiography. in poisoning by the organic phosphate cholinesterase inhibitors found in certain insecticides and by chemical warfare nerve gases, large doses of atropine relieve the muscarine-like symptoms and some of the central nervous system manifestations. it is also used as an antidote for mushroom poisoning due to muscarine in certain species such as amanita muscaria. atropine sulfate

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

leading pharma, llc - diphenoxylate hydrochloride (unii: w24od7yw48) (diphenoxylate - unii:73312p173g), atropine sulfate (unii: 03j5ze7ka5) (atropine - unii:7c0697dr9i) - diphenoxylate hydrochloride and atropine sulfate tablets are indicated as adjunctive therapy in the management of diarrhea in patients 13 years of age and older. diphenoxylate hydrochloride and atropine sulfate tablets are contraindicated in: - pediatric patients less than 6 years of age due to the risks of respiratory and central nervous system (cns) depression (see warnings ). - patients with diarrhea associated with pseudomembranous enterocolitis (clostridium difficile) or other enterotoxin-producing bacteria due to the risk of gastrointestinal (gi) complications, including sepsis (see warnings ). - patients with known hypersensitivity to diphenoxylate or atropine. - patients with obstructive jaundice. controlled substance: diphenoxylate hydrochloride and atropine sulfate tablets are classified as a schedule v controlled substance by federal regulation. diphenoxylate hydrochloride is chemically related to the narcotic analgesic meperidine. drug abuse and dependence: in doses used for the treatment of dia

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

eci pharmaceuticals, llc - diphenoxylate hydrochloride (unii: w24od7yw48) (diphenoxylate - unii:73312p173g), atropine sulfate (unii: 03j5ze7ka5) (atropine - unii:7c0697dr9i) - diphenoxylate hydrochloride and atropine sulfate tablets are indicated as adjunctive therapy in the management of diarrhea in patients 13 years of age and older. diphenoxylate hydrochloride and atropine sulfate tablets are contraindicated in: - pediatric patients less than 6 years of age due to the risks of respiratory and central nervous system (cns) depression (see warnings ). - patients with diarrhea associated with pseudomembranous enterocolitis ( clostridium difficile ) or other enterotoxin-producing bacteria due to the risk of gastrointestinal (gi) complications, including sepsis (see warnings ). - patients with known hypersensitivity to diphenoxylate or atropine. - patients with obstructive jaundice. diphenoxylate hydrochloride and atropine sulfate tablets are classified as a schedule v controlled substance by federal regulation. diphenoxylate hydrochloride is chemically related to the narcotic analgesic meperidine. in doses used for the treatment of diarr

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - diphenoxylate hydrochloride (unii: w24od7yw48) (diphenoxylate - unii:73312p173g), atropine sulfate (unii: 03j5ze7ka5) (atropine - unii:7c0697dr9i) - diphenoxylate hydrochloride and atropine sulfate tablets are indicated as adjunctive therapy in the management of diarrhea in patients 13 years of age and older. diphenoxylate hydrochloride and atropine sulfate tablets are contraindicated in: - pediatric patients less than 6 years of age due to the risks of respiratory and central nervous system (cns) depression (see warnings ). - patients with diarrhea associated with pseudomembranous enterocolitis (clostridium difficile) or other enterotoxin-producing bacteria due to the risk of gastrointestinal (gi) complications, including sepsis (see warnings ). - patients with known hypersensitivity to diphenoxylate or atropine. - patients with obstructive jaundice. controlled substance: diphenoxylate hydrochloride and atropine sulfate tablets are classified as a schedule v controlled substance by federal regulation. diphenoxylate hydrochloride is chemically related to the narcotic analgesic meperidine. drug abuse and dependence: in doses used for the treatment of diarrhea, whether acute or chronic, diphenoxylate has not produced addiction. diphenoxylate hydrochloride is devoid of morphine-like subjective effects at therapeutic doses. at high doses it exhibits codeine-like subjective effects. the dose which produces antidiarrheal action is widely separated from the dose which causes central nervous system effects. the insolubility of diphenoxylate hydrochloride in commonly available aqueous media precludes intravenous self- administration. a dose of 100 to 300 mg/day, which is equivalent to 40 to 120 tablets, administered to humans for 40 to 70 days, produced opiate withdrawal symptoms. since addiction to diphenoxylate hydrochloride is possible at high doses, the recommended dosage should not be exceeded.